This article has been corrected. See "Erratum: Effects of Individual Education Using a Treating-to-target Strategy in Patients with Rheumatoid Arthritis" in Volume 26 on page 85.
Abstract
Objective
To examine effects of an individual education program using the treating rheumatoid arthritis to target (RA T2T) strategy in patients with moderate-severe rheumatoid arthritis.
Methods
Patients were assigned randomly to an educational intervention (n=33) or conventional care group (n=33). The intervention was a nurse-delivered 9-month educational program consisting of 3 monthly sessions and monthly telephone counseling. The assessments occurred at the baseline and every 3 months in both groups, but only the intervention group completed the 9-month education follow-up. The outcome variables included the disease activity (DAS28), functional disability (KHAQ), fatigue (FACIT-Fatigue), and quality of life (SF-36). Repeated measures ANOVA and a Bonferroni multiple comparison were used to evaluate the outcome variables comparing the groups and follow-up times.
Results
Significant interactions were observed between the groups and follow-up times in the disease activity (p=0.041), fatigue (p=0.042), and physical (p=0.006) and mental (p=0.031) health-related quality of life, but there was no significant interaction in the functional disability (p=0.110). Significant differences were noted between the groups at the 9-month period (p=0.048) in disease activity and fatigue, and at the 6-month (p=0.023) and 9-month periods (p=0.027) in the physical health-related quality of life.
Conclusion
This education program using the RA T2T strategy had significant benefits on the disease activity, fatigue, and quality of life in patients with moderate to severe rheumatoid arthritis, and the results suggested that this contributed to positive clinical outcomes as a good practical nursing intervention.
REFERENCES
2. Korean College of Rheumatology. KCR textbook of rheumatology;Seoul, Koonja: 2014.
3. Gong G, Mao J. Health-related quality of life among Chinese patients with rheumatoid arthritis: the predictive roles of fatigue, functional disability, self-efficacy, and social support. Nurs Res. 2016; 65:55–67.
4. Welsing PM, van Gestel AM, Swinkels HL, Kiemeney LA, van Riel PL. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum. 2001; 44:2009–17.
5. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010; 69:631–7.
6. Pollard LC, Choy EH, Gonzalez J, Khoshaba B, Scott DL. Fatigue in rheumatoid arthritis reflects pain, not disease activity. Rheumatology (Oxford). 2006; 45:885–9.
7. Georgopoulou S, Prothero L, Lempp H, Galloway J, Sturt J. Motivational interviewing: relevance in the treatment of rheumatoid arthritis? Rheumatology (Oxford). 2016; 55:1348–56.
8. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31:315–24.
9. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/ European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010; 62:2569–81.
10. Fransen J, van Riel PL. The disease activity score and the EULAR response criteria. Clin Exp Rheumatol. 2005; 23(5 Suppl 39):S93–9.
11. Abourazzak F, El Mansouri L, Huchet D, Lozac'hmeur R, Hajjaj-Hassouni N, Ingels A, et al. Long-term effects of therapeutic education for patients with rheumatoid arthritis. Joint Bone Spine. 2009; 76:648–53.
12. Bae SC, Cook EF, Kim SY. Psychometric evaluation of a Korean Health Assessment Questionnaire for clinical research. J Rheumatol. 1998; 25:1975–9.
13. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980; 23:137–45.
14. Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J. Validation of the functional assessment of chronic illness therapy fatigue scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol. 2005; 32:811–9.
15. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992; 30:473–83.
16. Zangi HA, Ndosi M, Adams J, Andersen L, Bode C, Boström C, et al. EULAR recommendations for patient education for people with inflammatory arthritis. Ann Rheum Dis. 2015; 74:954–62.
17. van Lankveld W, van Helmond T, Näring G, de Rooij DJ, van den Hoogen F. Partner participation in cognitive-behavioral self-management group treatment for patients with rheumatoid arthritis. J Rheumatol. 2004; 31:1738–45.
18. Grønning K, Skomsvoll JF, Rannestad T, Steinsbekk A. The effect of an educational programme consisting of group and individual arthritis education for patients with poly-arthritis–a randomised controlled trial. Patient Educ Couns. 2012; 88:113–20.
19. Grønning K, Rannestad T, Skomsvoll JF, Rygg LØ, Steinsbekk A. Long-term effects of a nurse-led group and individual patient education programme for patients with chronic inflammatory polyarthritis – a randomised controlled trial. J Clin Nurs. 2014; 23:1005–17.
20. Park IH. Effects of empowerment education program for the patients having rheumatoid arthritis on empowerment, health status and self-care activities [thesis]. Seoul: Chung-Ang University;. 2001.
21. Lee EN, Choi EO, Hwang EJ. The effects of a self-help empowerment strategy program on the empowerment and health status of rheumatoid arthritis patients. J Korean Acad Adult Nurs. 2003; 15:393–401.
22. Masiero S, Boniolo A, Wassermann L, Machiedo H, Volante D, Punzi L. Effects of an educational-behavioral joint protection program on people with moderate to severe rheumatoid arthritis: a randomized controlled trial. Clin Rheumatol. 2007; 26:2043–50.
23. Helliwell PS, O'Hara M, Holdsworth J, Hesselden A, King T, Evans P. A 12-month randomized controlled trial of patient education on radiographic changes and quality of life in early rheumatoid arthritis. Rheumatology (Oxford). 1999; 38:303–8.
24. Giraudet-Le Quintrec JS, Mayoux-Benhamou A, Ravaud P, Champion K, Dernis E, Zerkak D, et al. Effect of a collective educational program for patients with rheumatoid arthritis: a prospective 12-month randomized controlled trial. J Rheumatol. 2007; 34:1684–91.
26. Hewlett S, Cockshott Z, Byron M, Kitchen K, Tipler S, Pope D, et al. Patients' perceptions of fatigue in rheumatoid arthritis: overwhelming, uncontrollable, ignored. Arthritis Rheum. 2005; 53:697–702.
27. Lorig K, Holman HR. Long-term outcomes of an arthritis self-management study: effects of reinforcement efforts. Soc Sci Med. 1989; 29:221–4.
28. Kim EJ. Influencing factors on quality of life in patients with rheumatoid arthritis [thesis]. Gimhae: Inje University;. 2011.
29. Cho SK, Kim D, Jun JB, Bae SC, Sung YK. Factors influencing quality of life (QOL) for Korean patients with rheumatoid arthritis (RA). Rheumatol Int. 2013; 33:93–102.
30. Kim HJ. The effects of self-management program on self-efficacy and quality of life for women with rheumatoid arthritis [thesis]. Suwon: Ajou University;. 2008.
Table 1.
Table 2.
Characteristics | Experimental group (n=33) | Control group (n=33) | t or χ2 | p-value |
---|---|---|---|---|
Age (yr) | 45.88±11.66 | 46.48±12.74 | −0.20 | 0.841 |
Gender | * | 0.999 | ||
Female | 30 (90.91) | 29 (87.88) | ||
Male | 3 (9.09) | 4 (12.12) | ||
Educational level | 0.00 | 0.999 | ||
≤ High school | 14 (42.42) | 15 (45.45) | ||
≥ College | 19 (57.58) | 18 (54.55) | ||
Job | 0.00 | 0.999 | ||
Yes | 19 (57.58) | 18 (54.55) | ||
No | 14 (42.42) | 15 (45.45) | ||
Regular exercise | 1.07 | 0.302 | ||
Yes | 9 (27.27) | 14 (42.42) | ||
No | 24 (72.73) | 19 (57.58) | ||
Height (cm) | 160.58±6.29 | 160.48±5.76 | 0.06 | 0.951 |
Weight (kg) | 56.76±10.80 | 59.18±12.12 | −0.86 | 0.394 |
Disease duration (mo) Methotrexate use | 57.36±72.21 | 59.67±75.79 | −0.13 * | 0.900 0.999 |
Yes | 31 (93.94) | 31 (93.94) | ||
No | 2 (6.06) | 2 (6.06) | ||
Steroid use | * | 0.258 | ||
Yes | 31 (93.94) | 27 (81.82)) | ||
No Rheumatoid factor | 2 (6.06) | 6 (18.18) | * | 0.999 |
Positive | 33 (100) | 32 (96.97) | ||
Negative | 0 (0) | 1 (3.03) | ||
ESR (mm/h) | 42.00±15.97 | 40.76±19.60 | 0.28 | 0.779 |
DAS28 (score) | 4.61±0.83 | 4.53±1.06 | 0.36 | 0.723 |
KHAQ (score) | 0.70±0.56 | 0.76±0.63 | −0.39 | 0.701 |
FACIT-F (score) | 32.42±12.32 | 33.03±10.07 | −0.22 | 0.828 |
Quality of life (SF-36 score) | ||||
Physical component summ | mary 38.21±7.26 | 39.04±7.86 | −0.44 | 0.658 |
Mental component summ | mary 44.35±9.23 | 46.18±11.72 | −0.71 | 0.483 |
Table 3.
Time | Remission achievement | Experimental group (n=33) | Control group (n=33) | χ2 | p-value |
---|---|---|---|---|---|
3 months | Yes | 8 (24.24) | 1 (3.03) | * | 0.027 |
No | 25 (75.76) | 32 (96.97) | |||
6 months | Yes | 14 (42.42) | 4 (12.12) | 6.19 | 0.013 |
No | 19 (57.58) | 29 (87.88) | |||
9 months | Yes | 15 (45.45) | 7 (21.21) | 3.34 | 0.068 |
No | 18 (54.55) | 26 (78.79) |